-
CIAV Replication Depends on Host CK2α and VP2
2026-09-08
Ma et al. identify host CK2α as an essential cellular factor that binds and stabilizes CIAV VP2, thereby supporting viral replication and disease. Their combination of kinase perturbation, VP2 residue analysis, reverse genetics, and animal infection experiments defines the VP2 S182/D183–CK2α interface as a mechanistically grounded antiviral target.
-
Berberine Hydrochloride: A Mechanism-First Guide
2026-09-07
Berberine hydrochloride connects metabolic signaling, microbial ecology, and osteoimmune biology in a research-ready framework. This guide focuses on assay attribution, formulation controls, and the translational limits of evidence relevant to hypoglycemic agent research and gut–bone studies.
-
PX-478 2HCl: From Hypoxia Biology to Translation
2026-09-07
A translational framework for using PX-478 2HCl to interrogate HIF-1α biology across cancer cell line hypoxia studies, radiosensitization experiments, and in vivo tumor ischemia models—while connecting mechanistic lessons from sepsis-associated kidney injury research to rigorous cancer investigation.
-
10058-F4: c-Myc-Max Workflow Guide
2026-09-05
Build mechanism-first experiments around 10058-F4, from c-Myc/Max disruption and apoptosis assay design to acute myeloid leukemia and prostate cancer models. This guide combines formulation controls, orthogonal readouts, reference-study insights, and practical troubleshooting for more interpretable results.
-
Saracatinib (AZD0530) Applied Research Workflows
2026-09-04
Saracatinib (AZD0530) provides a practical way to interrogate Src/Abl-dependent proliferation, motility, and tumor signaling across complementary assay formats. This guide connects cancer-focused workflows with a carefully bounded neuroscience application inspired by Reelin–SFK research, while emphasizing controls, dose selection, and troubleshooting.
-
Chemotherapy Enhances Neoantigen T Cell Therapy
2026-09-04
The 2025 Cell Reports Medicine study identifies the KRAS.G12V-specific TCR T104 and shows that lymphodepleting chemotherapy can improve neoantigen presentation as well as T-cell-mediated tumor killing. Its mechanistic contribution is the connection between chemotherapy-induced immunoproteasome activity, increased HLA-I expression, and remodeling of the tumor immunopeptidome.
-
Cabazitaxel: Workflow Guide for Resistant Models
2026-09-03
Cabazitaxel (XRP6258, SKU B2157) is a semi-synthetic taxane derivative for studying microtubule dynamics disruption and antiproliferative responses in cancer cell models, including taxane-resistant systems. It should be prepared in DMSO or ethanol rather than water, stored as a solid at -20°C, and used promptly after solution preparation.
-
CX-4945 (Silmitasertib) Workflow Guide
2026-09-03
Build reproducible CK2 inhibition experiments with CX-4945 (Silmitasertib), from DMSO stock preparation through pathway, apoptosis, cell-cycle, and resistance readouts. The workflow connects product-level potency data with a lung cancer study that used CK2 inhibition to interrogate ECE-1c stability, stemness, cisplatin resistance, and invasion.
-
Sabutoclax: Pan-Bcl-2 Inhibitor Assay Guide
2026-09-02
Sabutoclax supports mechanism-focused cancer experiments that distinguish growth suppression from true apoptosis. Its broad Bcl-2 family coverage, membrane permeability, and activity in prostate, lung, and lymphoma models make it useful for concentration-response profiling, pathway validation, and translational assay design.
-
SLU-PP-332 and ERRα Agonists: A Focused Review
2026-09-02
This focused minireview positions SLU-PP-332 as a preclinical exercise mimetic that activates ERRα-linked transcriptional programs for mitochondrial biogenesis, fatty acid oxidation, and glucose regulation. Its main contribution is a balanced synthesis of mechanistic evidence, comparative ERR pharmacology, and translational barriers, especially the safety implications of pan-ERR activity and the lack of human data.
-
FOXL2–RhoA/ROCK Control of Granulosa Cell Shape
2026-09-01
A 2024 study in chicken pre-ovulatory follicles identifies a direct FOXL2–RhoA/ROCK axis that reorganizes granulosa-cell actin and regulates cell expansion. By combining FOXL2 ChIP-seq, gene perturbation, cytoskeletal analysis, and pharmacological pathway inhibition, the work connects a follicular transcription factor to a defined mechanism of cellular morphology.
-
10058-F4: c-Myc-Max Inhibition Workflows
2026-09-01
10058-F4 offers a small-molecule route to interrupt c-Myc/Max signaling and connect transcription-factor perturbation with apoptosis, differentiation, and tumor-model readouts. This practical guide covers dosing setup, orthogonal validation, AML and prostate cancer applications, and troubleshooting for reproducible experiments.
-
NAD+ and Energy Stress: Beyond Canonical Autophagy
2026-08-31
NAD+ research is moving beyond simple cofactor replacement toward a more precise view of redox balance, enzyme consumption, AMPK–ULK1 signaling, and stress recovery. This thought-leadership guide shows how translational researchers can use Nicotinamide Adenine Dinucleotide in mechanistically resolved metabolic and autophagy assays.
-
Glioblastoma Apoptotic Priming and BH3-Mimetics
2026-08-31
The reference study shows that glioblastoma, including patient-derived stem-like cells, is unusually dependent on anti-apoptotic BCL-xL and MCL-1 for survival. Its central translational insight is that sequential inhibition of these BCL-2 family proteins can produce strong antitumor responses in vivo without overt toxicity, highlighting apoptotic priming as a therapeutic vulnerability.
-
Anisomycin as a Causal Probe of JNK and Memory
2026-08-30
Anisomycin is a potent JNK agonist for dissecting stress signaling, apoptosis, and experimental causality. This guide connects JNK perturbation with neuroligin 1 proteolysis and social-memory maintenance while defining the limits of that cross-domain interpretation.